ESTRO 2023 - Abstract Book

S1234

Digital Posters

ESTRO 2023

greater. Distribution of Gleason score 6, 7 and 8 or greater were 8.1%, 67.7% and 24%. Forty six percent of patients had positive margins. Median PSA of the entire cohort at the time of sRT was 0.27. Median PSA for group 1, 2 and 3 were 0.33, 0.26 and 0,2. Less than one third of patients of group 1 and 2 (26% and 32% respectively) had postoperative PSA of 0.2 ng/mL or less at the time of sRT. When analyzes were made between groups, only group 3 showed statistically significant differences in median PSA at the time of sRT compared to group 1 and group 2 (p<0.05). No differences were observed between group 1 and 2 (p=18).

Table 1

Figure 1 Median PSA for Group 1, Group 2 and Group 3

Conclusion RADICALS-RT demonstrated a significant impact on our clinical practice only after being supplemented with real local evidence. This information confirms the importance of real-world evidence complementing RCT in clinical practice. Clinician should be careful about adopting a sRT strategy if conditions are not appropriate. In this context, an aRT strategy should be revisited.

PO-1518 Stereotactic Body Radiation Therapy for adrenal metastases treated with Helical-Tomotherapy

J.M. Nieto-Guerrero Gomez 1 , M. Marti Laosa 1 , M.A. Gomez Aparicio 2 , E.M. Lozano Martin 2 , D. Carrasquilla de la Torre 1 , E. Jimenez Jimenez 1 1 Hospital General Universitario de Ciudad Real, Radiation Oncology, Ciudad Real, Spain; 2 Hospital Universitario de Toledo, Radiation Oncology, Toledo, Spain Purpose or Objective Stereotactic Body Radiation Therapy (SBRT) is a treatment option for patients with adrenal metastases. This study evaluated the impact and reported the tolerance of SBRT in adrenal metastases treated with Helical- Tomotherapy at Radiation Oncology Department of Ciudad Real Hospital. Materials and Methods This is a single-center retrospective study of patients with adrenal metastases treated with SBRT between January 2017 and March 2022.